"There were not many expectations regarding rate cut and hope was regarding a stoppage of moratorium and restructuring of loans. The RBI has acted judiciously by keeping rates unchanged due to surplus liquidity in the system and elevated forecast for inflation in Q2FY21," said Vinod Nair, Head of Research at Geojit Financial Services. … [Read more...] about Market gives thumbs up to RBI moves, are rate cuts not a trigger anymore?
Event planning tips
Cipla’s mantra of ‘Balancing growth with cost leadership’ reflects in its guidance of cost savings of ~Rs5bn in FY21 led by (1) leveraging digital technology in India branded formulations – marketing, promotions, conferences, product launches, (2) calibration of R&D – focussed products in inhalation. Cipla is hopeful of leveraging the digitization practice beyond FY21 and guided for healthy operating performance. Besides attaining cost efficiencies, it is working towards becoming the global leader in inhalation (Cipla is 2nd led by GSK). Cipla has been working on six inhalation products, with launches planned between FY21-25. Of the six, Albuterol (launched, MS-65%), ProAir (approved in 4Q, working on queries), Advair and Spiriva (filed), Symbicort (in clinics). It has also launched DHE nasal spray with 180-days exclusivity. We see increasing visibility over the medium-term earnings, given signs of improving execution in India and strong US build-out. … [Read more...] about Accumulate Cipla; target of Rs 804: Dolat Capital
Kashmir will cease to be a problem the day Pakistan stops meddling. Since 1947, they have sponsored terrorism, sabotaged development and exploited the religious sentiments of the people. They continue to create a noise around the so-called ‘atrocities’ in Kashmir at diplomatic, social, political and international levels. That’s the cause of the unrest in the Valley. … [Read more...] about Kashmiri Pandits have received only lip service from political parties, says author Avanti Sopory